Respiratory syncytial virus
Drug research and approvals for respiratory syncytial virus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 55 studies of respiratory syncytial virus are recruiting on ClinicalTrials.gov, Health Canada has authorized 50 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 55
- Trials authorized in Canada: 50
- FDA orphan approvals: 1
- EU medicines: 6
Recruiting Now
Newest start dates first, of 55 recruiting on ClinicalTrials.gov ↗- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High…NCT07908381 · Phase 2 / Phase 3 · Enanta Pharmaceuticals, Inc · starts Oct 19, 2026
- Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant RecipientsNCT07895394 · Phase 4 · Seoul National University Hospital · starts Oct 1, 2026
- Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV DiseaseNCT07839871 · Phase 3 · Pfizer · starts Sep 22, 2026
- rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderNCT07762014 · Phase 2 · Biothervax SpA · starts Sep 14, 2026
- A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsNCT07819097 · Phase 3 · Pfizer · starts Sep 9, 2026
- Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in…NCT07810010 · Phase 2 · Sanofi · starts Sep 9, 2026
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsNCT07768345 · Phase 3 · Pfizer · starts Aug 31, 2026
- Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)NCT07860216 · Phase 3 · Beijing BeneWill Technology Development Co., Ltd · starts Aug 21, 2026
- A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsNCT07764237 · Phase 1 · ModernaTX, Inc. · starts Aug 11, 2026
- A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 InjectionNCT07694557 · Phase 1 · Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · starts Jul 29, 2026
Trials Authorized in Canada
The 10 newest of 50; search them all in Canada trials| Sep 18, 2024 | A phase 3, global, randomized, modified double-blind, placebo-controlled, study to evaluate the efficacy, immunogenicity, and safety of ivx-a12, a respiratory…IVX-A12 | ICOSAVAX INC. (ICOSAVAX) (A MEMBER OF THE ASTRAZENECA GROUP OF COMPANIES) | Pending |
| Jun 3, 2024 | A phase 3 study to evaluate the efficacy, immunogenicity and safety of respiratory syncytial (rsv) perfusion f subunit vaccine in adultsABRYSVO | Pfizer | Ongoing |
| Mar 22, 2024 | A phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the rsvpref3 oa investigational vaccine in…RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE BIO RSV OA=ADJ (GSK3844766A) | GSK | Ongoing |
| Dec 5, 2023 | A phase 2, randomized, observer-blind, placebo-controlled, dose-escalation study to evaluate the reactogenicity, safety, and immunogenicity of mrna- 1345, an…MRNA-1345 | MODERNATX, INC. | Closed |
| Nov 2, 2023 | An interventional phase 2/3, adaptive, multi-center, randomized, double-blind study to investigate efficacy and safety of oral sisunatovir compared with…SISUNATOVIR (PF-07923568) | Pfizer | Ongoing |
| Aug 10, 2023 | An interventional, phase 1b, randomized, double-blind, sponsor-open, placebo-controlled, multi-center, dose-finding study to evaluate safety, tolerability and…SISUNATOVIR (PF-07923568) | Pfizer | Closed |
| Jun 30, 2023 | A phase 1, open-label, age-descending, dose-finding study and a phase 2/3, placebo-controlled, randomized, double-blind study to evaluate the safety,…PF-06928316 (RESPIRATORY SYNCYTIAL VIRUS [RSVPREF] VACCINE) | Pfizer | Pending |
| Jun 23, 2023 | A phase 3 study to evaluate the immunogenicity and safety of mrna-1345, an mrna vaccine targeting respiratory syncytial virus, in high-risk adultsMRNA-1345 | MODERNATX, INC. | Ongoing |
| Jun 8, 2023 | A phase 1, randomized, observer-blind, placebo-controlled, age de-escalation study of the safety, tolerability, and immunogenicity of mrna-1345 and mrna-1365…MRNA-1345 / MRNA-1365 | MODERNATX, INC. | Pending |
| Jun 1, 2023 | A phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of rsvpref3 oa investigational…RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION PROTEIN F3 OLDER ADULT (RSVPREF3… | GSK | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Jan 18, 1996 | RespigamFor the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary… | MedImmune & Massachussetts Public Health Biologics Labs. | Approved |
| Sep 27, 1990 | Respiratory Syncytial Virus Immune Globulin (human)Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children. | MedImmune, Inc. | Designated |
| Jan 3, 1989 | Aerosolized pooled immune globulinTreatment of respiratory syncytial virus lower respiratory tract disease. | Pediatric Pharmaceuticals, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Apr 15, 2026 | Enflonsiaclesrovimab | Merck Sharp Dohme Limited | EMA ↗ |
| Aug 22, 2024 | mResviarespiratory syncytial virus mRNA vaccine | Moderna Biotech Spain, S.L. | EMA ↗ |
| Aug 23, 2023 | Abrysvorespiratory syncytial virus vaccine (bivalent, recombinant) | Pfizer Europe MA EEIG | EMA ↗ |
| Jun 6, 2023 | ArexvyRespiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
| Oct 31, 2022 | Beyfortusnirsevimab | Sanofi Winthrop Industrie | EMA ↗ |
| Aug 13, 1999 | Synagispalivizumab | AstraZeneca AB | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA